Oltipraz

Overview

Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC 50 of Oltipraz for HIF-1α inhibition is 10 μM. Oltipraz is a potent Nrf2 activator.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase | Products > Signaling Pathways > HIV | Products > Signaling Pathways > Keap1-Nrf2 | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-12519
• CAS No.: 64224-21-1
• Molecular Formula: C8H6N2S3
• Molecular Weight: 226.34
• Purity: 99.87%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution
• Availability: In-stock

Source

Original product source